Is fosfomycin appropriate as a single oral dose for an adult with normal renal function who has an uncomplicated lower urinary tract infection caused by susceptible gram‑negative organisms?

Yes, fosfomycin is an excellent single-dose antibiotic for uncomplicated lower urinary tract infections in women.

A single 3-gram oral dose of fosfomycin trometamol is appropriate and recommended as first-line therapy for uncomplicated cystitis in adult women with normal renal function caused by susceptible gram-negative organisms, particularly E. coli. 1, 2, 3

Why Fosfomycin Works as Single-Dose Therapy

The pharmacokinetics uniquely support single-dose administration:

• Peak urinary concentrations reach 1053-4415 mg/L within 4 hours of a single 3-gram dose 4
• Therapeutic urinary levels (>128 mg/L) persist for 24-48 hours, far exceeding the minimum inhibitory concentration needed to kill most uropathogens 4, 5
• The drug is excreted unchanged in urine (38% recovery), achieving concentrations of ~700 mcg/mL at 2-4 hours and maintaining >100 mcg/mL for 48 hours 3
• No dosage adjustment needed in elderly patients or those with renal/hepatic impairment 5

Guideline-Supported Recommendations

Multiple high-quality guidelines endorse single-dose fosfomycin:

• IDSA/ESCMID 2011 guidelines recommend fosfomycin 3g single dose as appropriate first-line therapy for uncomplicated cystitis, citing minimal resistance and collateral damage 6
• American College of Physicians 2021 explicitly recommends fosfomycin as a single dose alongside nitrofurantoin (5 days) and TMP-SMX (3 days) for uncomplicated bacterial cystitis 1
• European Association of Urology 2024 lists fosfomycin trometamol 3g single dose as first-line treatment for uncomplicated cystitis in women 2
• FDA labeling specifically indicates fosfomycin for uncomplicated UTI (acute cystitis) in women ≥18 years 3

Clinical Efficacy Evidence

The single-dose regimen demonstrates comparable efficacy to multi-day courses:

• Bacteriologic cure rates of 78-87% at follow-up visits, comparable to 7-day nitrofurantoin (86%) and 5-day ciprofloxacin (65%) 7, 8
• Clinical success rates of 80%, matching longer treatment courses 7
• E. coli susceptibility remains high at 96% globally, including in both high-income and lower-middle-income countries 9
• Maintains activity against ESBL-producing and multidrug-resistant E. coli 6, 5

Important Caveats and Limitations

When NOT to Use Single-Dose Fosfomycin:

1. Pyelonephritis or upper tract infections - FDA labeling explicitly states fosfomycin is NOT indicated for pyelonephritis or perinephric abscess 3. Insufficient evidence supports oral fosfomycin for upper tract disease 10

2. Early pyelonephritis suspected - Guidelines recommend avoiding fosfomycin if upper tract involvement is possible 6

3. Men with UTI - Evidence and FDA approval are specific to women; men should receive 7-day courses of TMP-SMX or fluoroquinolones 2

4. Complicated UTIs - Structural/functional abnormalities, obstruction, or instrumentation require different approaches 1

Efficacy Considerations:

The IDSA guidelines acknowledge that fosfomycin has inferior bacterial eradication compared to other first-line agents based on FDA submission data, though clinical efficacy remains comparable 6. Unpublished data referenced in guidelines showed lower bacterial eradication versus 10-day TMP-SMX and 7-day ciprofloxacin 6.

Practical Prescribing Algorithm

For uncomplicated cystitis in women:

1. Confirm diagnosis: dysuria, frequency, urgency WITHOUT fever, flank pain, or systemic symptoms
2. Verify patient can take oral medication
3. Check for contraindications (pregnancy category B - generally safe) 4
4. Prescribe: Fosfomycin trometamol 3g single oral dose
5. Instruct: Mix sachet with water before ingesting; may take with or without food 3
6. Follow-up if symptoms persist beyond 2-3 days or recur within 2 weeks - obtain culture and switch to alternative agent 6, 2

Resistance and Stewardship Benefits

• Minimal collateral damage to intestinal flora due to single exposure 6
• No cross-resistance with β-lactams or aminoglycosides 3
• Resistance rates remain <1% in E. coli despite decades of use 5
• Spares fluoroquinolones for more serious infections, addressing antimicrobial stewardship goals 1, 11

Special Populations

• Pregnancy: Category B, considered safe 4, 5
• Elderly: No dosage adjustment required 3, 5
• VRE/MRSA: Active against vancomycin-resistant enterococci and MRSA in vitro, though clinical data for these indications remain limited 6

The convenience of single-dose therapy, excellent urinary concentrations, broad-spectrum activity including MDR organisms, and minimal adverse effects make fosfomycin an optimal choice for uncomplicated cystitis in women when other first-line agents cannot be used or in settings with high resistance to alternatives.